AGIO
Agios Pharmaceuticals Inc

2,639
Mkt Cap
$2.51B
Volume
735,186.00
52W High
$62.58
52W Low
$23.42
PE Ratio
-6.22
AGIO Fundamentals
Price
$43.24
Prev Close
$43.18
Open
$42.86
50D MA
$39.58
Beta
1.24
Avg. Volume
806,876.00
EPS (Annual)
$11.64
P/B
1.83
Rev/Employee
$74,790.98
Loading...
Loading...
News
all
press releases
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.
Zacks·18h ago
News Placeholder
More News
News Placeholder
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +7.77% and +27.69%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·14d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·24d ago
News Placeholder
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.
Zacks·2mo ago
News Placeholder
Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More
While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7.
Stocktwits·2mo ago
News Placeholder
Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·2mo ago
News Placeholder
Agios Retail Buzz Surges On Saudi Thalassemia Nod As Retail Hails ‘Incredible Recovery’ Despite FDA Concerns
Retail investors defended Agios on Stocktwits, saying reported deaths involved critically ill patients and didn’t reflect typical use.
Stocktwits·3mo ago
News Placeholder
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -10.92% and +34.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?
Zacks·5mo ago

Latest AGIO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.